Senicapoc in Alzheimer's Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Senicapoc in Alzheimer's Disease — Stella

Home/Mild Cognitive Impairment/

View on ClinicalTrials.gov

Recruiting

Back to Mild Cognitive Impairment trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

University of California, Davis Alzheimer's Disease Center, Sacramento, California

UC Davis Alzheimer's Disease Center East Bay, Walnut Creek, California

Key details

Phase

Safety & dosing

Sponsor

University of California, Davis

Collaborators

Alzheimer's Drug Discovery Foundation, Alzheimer's Association

Enrollment target

~55 participants

Started

March 2022

Primary completion

June 2026

Age range

55 Years – 85 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.